Verastem Oncology Raises $250M in Common Stock and Warrant Offering

  • Verastem Oncology priced a $250M offering of 30,937,500 shares of common stock at $8.00 per share and pre-funded warrants for 312,503 shares at $7.9999 per warrant.
  • The offering is expected to close on or about October 15, 2026, subject to customary closing conditions.
  • Proceeds will fund continued clinical development of product candidates, including the VS-7375 program, and for working capital and other general corporate purposes.
  • Jefferies, Guggenheim Securities, and Cantor are joint book-running managers, with B. Riley Securities as lead manager.

Verastem Oncology’s $250M offering underscores the biopharmaceutical company’s push to advance its pipeline, particularly in RAS/MAPK pathway-driven cancers. The move comes amid heightened competition in oncology drug development, where securing non-dilutive funding remains a strategic priority. The scale of the offering reflects both the urgency and the market’s appetite for late-stage oncology assets.

Clinical Development
How the $250M infusion will accelerate the VS-7375 program and other pipeline candidates.
Market Reaction
Whether the dilutive effect of the offering will impact Verastem’s stock price in the near term.
Execution Risk
The pace at which Verastem can translate the proceeds into tangible clinical and commercial progress.